FMP
Inhibrx Biosciences, Inc.
INBX
NASDAQ
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
14.1 USD
-0.05 (-0.355%)
Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
2.76B
1.76B
1.57B
1.39B
1.38B
1.18B
1B
853.43M
727.07M
619.42M
Revenue %
-
-36.34
-10.71
-11.56
-0.61
-14.81
-14.81
-14.81
-14.81
Operating Cash Flow
134.53M
19.82M
-133.01M
76.93M
62.37M
17.84M
15.2M
12.95M
11.03M
9.4M
Operating Cash Flow %
4.87
1.13
-8.47
5.54
4.52
1.52
1.52
1.52
1.52
Cap Ex
-33.71M
-36.27M
-27.65M
-23.55M
-23.6M
-19.87M
-16.93M
-14.42M
-12.29M
-10.47M
Cap Ex %
-1.22
-2.06
-1.76
-1.7
-1.71
-1.69
-1.69
-1.69
-1.69
Free Cash Flow
100.82M
-16.45M
-160.66M
53.38M
38.77M
-2.03M
-1.73M
-1.47M
-1.26M
-1.07M
Weighted Average Cost Of Capital
Price
1.91
Beta
Diluted Shares Outstanding
32.56M
Costof Debt
10.51
Tax Rate
After Tax Cost Of Debt
10.51
Risk Free Rate
Market Risk Premium
Cost Of Equity
Total Debt
366.79M
Total Equity
62.19M
Total Capital
428.98M
Debt Weighting
85.5
Equity Weighting
14.5
Wacc
9.25
Build Up Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
2.76B
1.76B
1.57B
1.39B
1.38B
1.18B
1B
853.43M
727.07M
619.42M
Operating Cash Flow
134.53M
19.82M
-133.01M
76.93M
62.37M
17.84M
15.2M
12.95M
11.03M
9.4M
Cap Ex
-33.71M
-36.27M
-27.65M
-23.55M
-23.6M
-19.87M
-16.93M
-14.42M
-12.29M
-10.47M
Free Cash Flow
100.82M
-16.45M
-160.66M
53.38M
38.77M
-2.03M
-1.73M
-1.47M
-1.26M
-1.07M
Wacc
9.25
9.25
9.25
9.25
9.25
Pv Lfcf
-1.86M
-1.45M
-1.13M
-881.81k
-687.64k
Sum Pv Lfcf
-6.01M
Terminal Value
Growth In Perpetuity Method
Long Term Growth Rate
Wacc
9.25
Free Cash Flow T1
-1.09M
Terminal Value
-15.06M
Present Terminal Value
-9.67M
Intrinsic Value
Enterprise Value
-15.68M
Net Debt
325.52M
Equity Value
-341.2M
Diluted Shares Outstanding
32.56M
Equity Value Per Share
-10.48
Projected DCF
-10.48 1.182%
